To investigate whether the in vitro metabolic vulnerability posed by MTAP deletion holds in human GBM tumors, we assessed PRMT5 activity by measuring SDMA levels in the same set of human tumors in which we performed metabolomics. This evidence concerns the gene MTAP and glioblastoma.